BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 12843865)

  • 1. [Use of low molecular weight heparins by dermatologists].
    Maakaroun A; Gruel Y
    Ann Dermatol Venereol; 2003 Apr; 130(4):473-8. PubMed ID: 12843865
    [No Abstract]   [Full Text] [Related]  

  • 2. Eczematous plaques related to unfractionated and low-molecular-weight heparins: cross-reaction with danaparoid but not with desirudin.
    Martin L; Machet L; Gironet N; Pouplard C; Gruel Y; Vaillant L
    Contact Dermatitis; 2000 May; 42(5):295-6. PubMed ID: 10789857
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful use of heparinoids in a pregnancy complicated by allergy to heparin.
    Taylor AA
    BJOG; 2001 Sep; 108(9):1011-2. PubMed ID: 11563455
    [No Abstract]   [Full Text] [Related]  

  • 4. [Delayed intracutaneous test reaction in heparin intolerance].
    Wurpts G; Merk HF
    Hautarzt; 2007 May; 58(5):394-6. PubMed ID: 17450341
    [No Abstract]   [Full Text] [Related]  

  • 5. Delayed-type skin reaction to the heparin-alternative danaparoid.
    Szolar-Platzer C; Aberer W; Kränke B
    J Am Acad Dermatol; 2000 Nov; 43(5 Pt 2):920-2. PubMed ID: 11044823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Delayed hypersensitivity to heparins and heparinoids].
    Nicolie B; Bonneau JC; Le Sellin J; Gay G; Leclere JM; Drouet M
    Allerg Immunol (Paris); 2002 Feb; 34(2):47-50. PubMed ID: 11933754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerance of fondaparinux in a patient allergic to heparins and other glycosaminoglycans.
    Ludwig RJ; Beier C; Lindhoff-Last E; Kaufmann R; Boehncke WH
    Contact Dermatitis; 2003 Sep; 49(3):158-9. PubMed ID: 14678213
    [No Abstract]   [Full Text] [Related]  

  • 8. Delayed-type hypersensitivity to subcutaneous heparin with tolerance of i.v. administration.
    Liew G; Campbell C; Thursby P
    ANZ J Surg; 2004 Nov; 74(11):1020-1. PubMed ID: 15550103
    [No Abstract]   [Full Text] [Related]  

  • 9. Alternative anticoagulation management strategies for the patient with heparin-induced thrombocytopenia undergoing cardiac surgery.
    Murphy GS; Marymont JH
    J Cardiothorac Vasc Anesth; 2007 Feb; 21(1):113-26. PubMed ID: 17289495
    [No Abstract]   [Full Text] [Related]  

  • 10. Danaparoid sodium.
    Acostamadiedo JM; Iyer UG; Owen J
    Expert Opin Pharmacother; 2000 May; 1(4):803-14. PubMed ID: 11249517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Successful therapy of heparin-associated thrombocytopenia with a low sulfated heparinoid].
    Herzog S; Rath W; Kuhn W
    Geburtshilfe Frauenheilkd; 1995 Mar; 55(3):164-6. PubMed ID: 7665065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current treatment concepts in heparin-induced thrombocytopenia].
    Ranze O; Greinacher A
    Dtsch Med Wochenschr; 1999 Jul; 124(28-29):865-73. PubMed ID: 10432950
    [No Abstract]   [Full Text] [Related]  

  • 13. Management of allergy to heparins in postoperative care: subcutaneous allergy and intravenous tolerance.
    Seitz CS; Brocker EB; Trautmann A
    Dermatol Online J; 2008 Sep; 14(9):4. PubMed ID: 19061586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Heparin induced thrombocytopenia and anticoagulation in renal replacemant therapy].
    Steinfeldt T; Rolfes C
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2008 Apr; 43(4):304-10; quiz 312. PubMed ID: 18409125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Hirsh J; Bauer KA; Donati MB; Gould M; Samama MM; Weitz JI
    Chest; 2008 Jun; 133(6 Suppl):141S-159S. PubMed ID: 18574264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lifesaving citrate anticoagulation to bridge ineffective danaparoid [correction of to bridge to danaparoid] treatment.
    Dworschak M; Hiesmayr JM; Lassnigg A
    Ann Thorac Surg; 2002 May; 73(5):1626-7. PubMed ID: 12022563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial.
    de Valk HW; Banga JD; Wester JW; Brouwer CB; van Hessen MW; Meuwissen OJ; Hart HC; Sixma JJ; Nieuwenhuis HK
    Ann Intern Med; 1995 Jul; 123(1):1-9. PubMed ID: 7539233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ardeparin and danaparoid for prevention of deep vein thrombosis.
    Med Lett Drugs Ther; 1997 Oct; 39(1011):94-5. PubMed ID: 9379998
    [No Abstract]   [Full Text] [Related]  

  • 19. Danaparoid: a review of its use in thromboembolic and coagulation disorders.
    Ibbotson T; Perry CM
    Drugs; 2002; 62(15):2283-314. PubMed ID: 12381232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Thrombopenia induced by heparin: treatment with Org 10172. Tolerability and efficacy].
    Tardy-Poncet B; Reynaud J; Tardy B; Mahul P; Mismetti P; Beraud AM; Rebaud MA; Bayon M; Guyotat D
    Presse Med; 1996 May 4-11; 25(16):751-5. PubMed ID: 8692750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.